Smith–Lemli–Opitz syndrome: a treatable inherited error of metabolism causing mental retardation

Małgorzata J.M. Nowaczyk,† MD; Donald T. Whelan, MD; Timothy W. Heshka,† MSc; Robert E. Hill,† PhD

Abstract

SMITH–LEMLI–OPITZ SYNDROME, a syndrome of multiple malformations and mental retardation that for years was relegated to the atlases of genetic esoterica, was recently found to be a relatively common inborn error of metabolism. The underlying defect is absent or deficient activity of 7-dehydrocholesterol-Δ7-reductase, the enzyme catalysing the final step of cholesterol synthesis. The discovery of the biochemical defect causing Smith–Lemli–Opitz syndrome has resulted in the development of a diagnostic test and a potentially beneficial treatment (dietary cholesterol supplementation). Infants and young children with the syndrome have shown marked improvement in growth, behaviour and general health after receiving cholesterol therapy; older children and adults have shown some improvement in development and intellectual functioning. Despite the excitement these developments have elicited among geneticists and biochemists, this syndrome remains relatively unknown to many primary care physicians. Increased awareness of Smith–Lemli–Opitz syndrome is needed to identify affected patients so that they and their families can benefit from appropriate treatment and genetic counselling.

Smith–Lemli–Opitz syndrome (SLOS) appears to be the second most common treatable recessive inherited error of metabolism causing mental retardation, after phenylketonuria. Its incidence is estimated to be between 1 in 40 000 and 1 in 20 000 births. SLOS is caused by a defect in cholesterol synthesis and presents with characteristic dysmorphic facial features, mental retardation, multiple congenital anomalies and failure to thrive. It was first described in 1964 and, until recently, was of limited clinical interest to primary care physicians because no diagnostic test or treatment was available.

In 1994 the discovery of the underlying defect that affects cholesterol synthesis led to the development of a biochemical diagnostic test for SLOS. With increasing use of this diagnostic test, it became apparent that the syndrome presents with a wide spectrum of clinical severity and that patients at either end of the clinical spectrum are often missed — mildly affected patients because of their very subtle physical findings and more severely affected patients because death or pregnancy termination occurred before the diagnosis was considered.

Despite the exciting research developments, we believe that this relatively common genetic disease remains unknown to primary care physicians. Because dietary therapy with cholesterol supplementation has been shown to have a considerable positive impact on the clinical course of this disease, increased physician awareness is needed to ensure that patients and their families receive appropriate diagnosis, treatment and genetic counselling.

Clinical features

SLOS is characterized by dysmorphic facial features, microcephaly, growth retardation, multiple internal anomalies, cutaneous syndactyly of the second and third toes, and genital malformations. Patients with SLOS have a broad and high forehead, bilateral ptosis, epicanthal folds, a broad nasal bridge, a short nose with an-
teverted nares and micrognathia. The ears are low set and small, and midline cleft palate is common. On occasion, newborns with SLOS have been mistakenly thought to have Down syndrome. However, the facial features may be subtle and difficult to recognize in both newborns and adults. The characteristic malformation of the feet (Fig. 1) is present in about 80% of patients with confirmed SLOS, but it may be very subtle. Polydactyly of feet and hands, oligodactyly of hands, short thumbs, hypoplastic thenar eminences and cleft feet are also common. The genital malformations observed in affected males include hypospadias, undescended testes and micropenis. The ease of detecting abnormalities of male external genitalia has led to a clinical diagnosis in more males with SLOS than in females with SLOS. Other malformations involving the brain, and respiratory, genitourinary and gastrointestinal systems have been reported in patients with more severe forms of SLOS. Overall there are no clinical features that are pathognomonic for the syndrome, and therefore it may be difficult to diagnose the condition on the basis of clinical findings alone; however, there are features that should prompt physicians to consider SLOS in the differential diagnosis of mental retardation (Table 1).

Patients with severe forms of the syndrome present with life-threatening congenital malformations of the central nervous system and heart, cystic kidney dysplasia and ambiguous genitalia and have an associated high neonatal mortality. Those with mild forms may present with mental deficits alone or accompanied by isolated cataracts, cleft palate or syndactyly. SLOS also has been diagnosed in mentally retarded adults (personal observation). Since the discovery of the biochemical defect associated with the syndrome, the clinical spectrum of this disease has expanded, and an increasing number of patients with subtle clinical findings are being reported.

In children with SLOS, feeding difficulties constitute a major problem during infancy, and supplemental enteral tube feeding may be required. However, despite adequate energy intake, failure to thrive frequently persists during infancy and childhood. Global developmental delay appears to occur universally among affected patients, who consequently require extensive care for their activities of daily living. Speech does not develop in most, but comprehension may be surprisingly good. Behavioural difficulties such as hyperactivity, frequent temper tantrums, violent outbursts, destruction of property and self-mutilation are common in children and adults and may cause a severe strain on family members (personal observation). Children with SLOS and minimal clinical findings had been diagnosed with autism or pervasive developmental disorder (Dr. Richard I. Kelley, Kennedy Krieger Institute, Baltimore: personal communication, 1999). Skin photosensitivity with marked reaction to sunlight is frequently observed. Secondary biochemical abnormalities may develop as a result of the cholesterol deficiency; these include deficiencies of steroid hormones and of bile acids. Bile acid deficiency can lead to fat malabsorption and fat-soluble vitamin deficiency, with resultant failure to thrive. Cholestatic liver disease in a number of patients with severe SLOS has been reported, and it can occur as part of the initial presentation in neonates.

**Genetics and epidemiology**

SLOS is an autosomal recessive disease, which implies that both parents of affected patients are obligate carriers. Thus, the parents have a 1-in-4 risk of recurrence with each subsequent pregnancy. The syndrome appears to be most common in the Caucasian population of North European origin, with infrequent reports in people of African or Japanese origin. In the Caucasian population, the carrier frequency is estimated to be 1 in 70 people. Because of the high carrier rate, genetic counselling for more distant family members should be offered as well.

Recently the gene for 7-dehydrocholesterol-∆'-reductase was mapped to chromosome 11q12-13, and mutations in this gene were found in a number of patients with SLOS. Future studies should prospectively determine

**Table 1: Clinical indications for 7-dehydrocholesterol measurement in diagnostic testing for Smith–Lemli–Opitz syndrome (SLOS)**

| Developmental delay of unknown cause and any of the following: |
| Facial features suggestive of SLOS | Syndactyly of the second and third toes | Hand anomalies | Genital anomalies | Intrauterine growth retardation and low birth weight | Failure to thrive | Feeding difficulties necessitating enteral tube feeding | Cleft palate | Autistic features | Family history of SLOS |
| Abnormally low unconjugated estriol level detected through maternal serum screening | Clinical diagnosis of Down syndrome, but normal chromosomes | Previous clinical diagnosis of SLOS |

**Fig. 1: Cutaneous Y-syndactyly of the second and third toes and “fork-toe” appearance characteristic of Smith–Lemli–Opitz syndrome (SLOS).**
the incidence of SLOS, and mutation analysis is hoped to allow more accurate carrier testing in the future.

Biomedical defect and diagnosis

The inherited biochemical defect is a deficiency of 7-dehydrocholesterol-A*-reductase, the catalyst in the last step of cholesterol synthesis: the conversion of 7-dehydrocholesterol (7-DHC) to cholesterol. Because of this enzymatic deficiency, there is a generalized cholesterol deficiency and an accumulation of 7-DHC in all body tissues. Cholesterol is a major constituent of cell membranes and myelin and is necessary for the synthesis of steroid hormones and bile acids. The severity of the clinical presentation and mortality of SLOS correlates well with the extent of the cholesterol deficiency. Secondary deficiencies of steroid hormones may be present in most patients with severe disease.

In any child or adult with idiopathic mental retardation, a genetic consultation should be considered and, if indicated, diagnostic testing should be performed (Fig. 2).

Prenatal diagnosis and screening

Families in whom a patient with SLOS has been identified should be aware of the 25% recurrence rate and the availability of prenatal diagnosis. Before the biochemical defect was discovered, ultrasonography was used to detect characteristic birth defects in pregnancies at risk for SLOS. Increased nuchal-fold thickness at 13 to 14 weeks’ gestation may be the first ultrasonographic sign that the fetus has SLOS. A detailed ultrasound examination at 18 to 20 weeks’ gestation may detect some of the severe malformations, but it does not detect subtle abnormalities of the face, hands and feet.

Prenatal diagnosis is now based on the detection of 7-DHC and a related compound, 8-DHC, in amniotic fluid any time after 13 weeks’ gestation. A carrier couple may want to consider a number of reproductive choices such as termination of an affected pregnancy, adoption or artificial insemination. If a couple wishes to continue with an affected pregnancy, maternal cholesterol supplementation has been reported; however, there is limited follow-up regarding the efficacy of this treatment.

SLOS should also be considered whenever a low unconjugated estriol (uE3) level is detected as part of triple-marker maternal serum screening for Down’s syndrome and open spina bifida. Because steroid hormones such as uE3 are derived from cholesterol and because cholesterol synthesis is diminished in fetuses with SLOS, mothers with affected fetuses have abnormally low uE3 levels. Screening for SLOS in families who are not known to be at increased risk (i.e., no family history of the disease) may become part of maternal serum screening. A prospective multicentre study is under way that will evaluate the clinical utility of screening for SLOS as part of maternal serum screening (Dr. Richard I. Kelley, Kennedy Krieger Institute, Baltimore: personal communication, 1998).

![Figure 2: Diagnostic approach to mental retardation. *Investigations based on recommendations of Curry and associates. †Urine metabolic screen may include qualitative detection of reducing substances, ketones, thiosulfite, branched chain amino acids, tyrosine, disulfides and other tests.](Image 528x722 to 552x752)
invasive tests to screen for SLOS using maternal urine are currently being developed.

Treatment

The goal of treatment is to provide enough dietary cholesterol to return the plasma cholesterol level to normal. The usual starting dose is 40–50 mg/kg daily, with increases based on somatic growth requirements. Dietary cholesterol can be given either in a natural form (e.g., eggs, cream) or as purified food-grade cholesterol. Because of feeding difficulties in infants and younger children who have SLOS, and because the diet is usually unpalatable to older children, enteral tube feeding is often required.

Dietary cholesterol supplementation can restore a normal growth pattern in children and adolescents with SLOS, alleviate behavioural abnormalities and improve general health (e.g., fewer infections, improved gut motility, onset of puberty). Furthermore, cholesterol supplementation appears to be effective in old and young patients alike; therefore, delays in diagnosing SLOS should not deter initiation of treatment. Behavioural changes typically occur before any changes in the plasma cholesterol level; this has also been observed in adults with SLOS who have received cholesterol therapy. However, a significant

Clinical reports

The following cases illustrate the difficulty in diagnosing SLOS based on clinical features alone and the potential benefits of cholesterol supplementation. The second report is a composite based on several cases managed by us and other colleagues (Dr. Annette S.J. Feigenbaum, Hospital for Sick Children, Toronto: personal communication, 1998); the cases described in the third report have been reported previously.

Report 1

This girl was born at term to a 29-year-old woman. Results of maternal serum screening at 16 weeks’ gestation were negative for Down syndrome and open neural tube defects; the unconjugated estriol level was 1.00 mmol/L, or 0.27 multiples of the mean. Ultrasound examination at 18 weeks’ gestation was reported as normal. Intrauterine growth retardation was noted at 36 weeks, and labour was induced at 38 weeks because of lack of interim growth.

Birth weight and length were appropriate for gestational age (10th percentile), but there was relative microcephaly (third percentile). The baby had facial features typical of SLOS: small chin, cleft palate, abnormally shaped skull, abnormal hands and syndactyly of the second and third toes (Fig. 1). The external genitalia were normal and female in appearance. A genetic consultation was requested because of suspected Down syndrome.

The baby had a normal female karyotype. The plasma cholesterol level was less than 1.10 mmol/L and the plasma 7-DHC level 200 mmol/L, thereby confirming the clinical diagnosis of SLOS. Cholesterol supplementation was started, but difficulties with oral feeding led to the placement of a percutaneous gastric tube at 2 months of age. At 10 months, the girl was below the third percentile for head circumference, weight and length, but her rate of growth had increased. She was cooing, laughing, rolling and smiling respondively with good eye contact.

Report 2

This 15-year-old boy was born following an uncomplicated pregnancy and delivery. Growth parameters were normal, but he had a cleft palate, small chin, hypospadias and undescended testes. Chromosomal analysis demonstrated a normal male karyotype. Feeding problems soon after birth resulted in the need for nasogastric tube feeding. A clinical diagnosis of SLOS was made at the age of 20 months based on the following features: microcephaly, long and narrow skull, bilateral epicanthal folds, broad nasal bridge, cleft palate, bilateral ptosis and bilateral cutaneous syndactyly of the second and third toes.

The child underwent surgical correction of his congenital malformations without complications. His general

Fig. 3: Two brothers with facial features typical of SLOS: ptosis, epicanthal folds, small chin and short nose. The facial features are more pronounced in the younger brother (right).
Dietary therapy is monitored by growth parameters (i.e., body weight and length, and head circumference), behavioural and neurologic assessments, and biochemical testing (i.e., plasma cholesterol and 7-DHC levels). A multidisciplinary team approach is helpful in providing optimal care for children with SLOS and for their families.

We thank Drs. Richard I. Kelley and Hillary Vallance for their reviews of the manuscript, Mrs. Melanie Flokstra and Ms. Del Hurst for secretarial assistance, Mrs. Donna McCaughey for technical assistance and Ms. Joan DiStefano, BASc, RD, for dietary management of the patients. We also thank Dr. James D. Douketis for his extensive help and support with this project.

Permission to publish the clinical reports and photographs of the children was received from the parents.

Competing interests: None declared.

References


Reprint requests to: Dr. Małgorzata J.M. Nowaczyk, McMaster University Medical Centre, Rm. 3N16, 1200 Main St. W, Hamilton ON L8N 3Z5; fax 905 521-2651; nowaczyk@fm.mcmaster.ca

Want to search MEDLINE?

OSLER (Ovid Search: Link to Electronic Resources) provides CMA members with

- free access to MEDLINE
- free access to HealthStar, AIDSLINE and CancerLit
- free librarian support

More than 4000 physicians — almost 10% of CMA members — are using the CMA's free online search service. To register: [www.cma.ca/osler](http://www.cma.ca/osler)

For information:

Deidre Green

OSLER Support Librarian

800 663-7336 x2255

cmalibrary@sympatico.ca

OASIS (Ovid Search: Link to Electronic Resources) provides non-CMA members with

- free access to MEDLINE
- free access to HealthStar, AIDSLINE and CancerLit
- free librarian support

OSLER (Ovid Search: Link to Electronic Resources) provides CMA members with

- free access to MEDLINE
- free access to HealthStar, AIDSLINE and CancerLit
- free librarian support

More than 4000 physicians — almost 10% of CMA members — are using the CMA's free online search service. To register: [www.cma.ca/osler](http://www.cma.ca/osler)